![EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease - Journal of Hepatology EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease - Journal of Hepatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/94795d16-bb69-4094-9032-2ef49774666f/gr1.jpg)
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease - Journal of Hepatology
![Identification of Molecular Markers for Liver Cirrhosis by Single-nucleus Rna Sequencing - ATC Abstracts Identification of Molecular Markers for Liver Cirrhosis by Single-nucleus Rna Sequencing - ATC Abstracts](https://atcmeetingabstracts.com/wp-content/uploads/2021/04/g6246_1.jpg)
Identification of Molecular Markers for Liver Cirrhosis by Single-nucleus Rna Sequencing - ATC Abstracts
![Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression | Future Science OA Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression | Future Science OA](https://www.future-science.com/cms/10.4155/fsoa-2017-0083/asset/images/medium/figure2.gif)
Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression | Future Science OA
![MSDC-0602K shows potential for improving markers of liver disease in individuals with nonalcoholic steatohepatitis (NASH) - The International Liver Congress™ 2019, EASL 2019 MSDC-0602K shows potential for improving markers of liver disease in individuals with nonalcoholic steatohepatitis (NASH) - The International Liver Congress™ 2019, EASL 2019](https://2019.ilc-congress.eu/wp-content/uploads/2019/04/easl-press-release-MAT.png)
MSDC-0602K shows potential for improving markers of liver disease in individuals with nonalcoholic steatohepatitis (NASH) - The International Liver Congress™ 2019, EASL 2019
![Discovery, validation and sequencing of urinary peptides for diagnosis of liver fibrosis—A multicentre study - eBioMedicine Discovery, validation and sequencing of urinary peptides for diagnosis of liver fibrosis—A multicentre study - eBioMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a3557bfa-a69a-41fb-9f09-bd9bd05d746a/gr1.jpg)
Discovery, validation and sequencing of urinary peptides for diagnosis of liver fibrosis—A multicentre study - eBioMedicine
![GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease - Gastroenterology GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease - Gastroenterology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/133ebdd4-1d91-4d5c-aa55-5d8c64f77ef7/gr1.jpg)
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease - Gastroenterology
![Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review - The Lancet Gastroenterology & Hepatology Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review - The Lancet Gastroenterology & Hepatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2091737320/2076224917/gr1.gif)
Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review - The Lancet Gastroenterology & Hepatology
Panel of three novel serum markers predicts liver stiffness and fibrosis stages in patients with chronic liver disease | PLOS ONE
![The Virta Clinical Trial Outcomes at 1 Year Demonstrate Improved Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes The Virta Clinical Trial Outcomes at 1 Year Demonstrate Improved Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes](https://assets-global.website-files.com/5dc45139b3f0c9259aecd32b/5dc45139b3f0c975e4ecd8a3_FINAL-PT-Infographic-Effects-on-NAFLD-Markers-1-Alternative.1.jpeg)
The Virta Clinical Trial Outcomes at 1 Year Demonstrate Improved Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes
![Liver blood tests: how to interpret abnormal results | Implementing guidelines | Guidelines in Practice Liver blood tests: how to interpret abnormal results | Implementing guidelines | Guidelines in Practice](https://d9qc22597pyja.cloudfront.net/Pictures/1024x536/6/8/5/2685_figure1_liver_49480.png)